These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 26208433)
21. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma. Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533 [TBL] [Abstract][Full Text] [Related]
22. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis. Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839 [TBL] [Abstract][Full Text] [Related]
23. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863 [TBL] [Abstract][Full Text] [Related]
24. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer. Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822 [TBL] [Abstract][Full Text] [Related]
25. Isorhamnetin augments the anti-tumor effect of capecitabine through the negative regulation of NF-κB signaling cascade in gastric cancer. Manu KA; Shanmugam MK; Ramachandran L; Li F; Siveen KS; Chinnathambi A; Zayed ME; Alharbi SA; Arfuso F; Kumar AP; Ahn KS; Sethi G Cancer Lett; 2015 Jul; 363(1):28-36. PubMed ID: 25827070 [TBL] [Abstract][Full Text] [Related]
26. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma. Suarez-Kelly LP; Kemper GM; Duggan MC; Stiff A; Noel TC; Markowitz J; Luedke EA; Yildiz VO; Yu L; Jaime-Ramirez AC; Karpa V; Zhang X; Carson WE Oncotarget; 2016 Dec; 7(49):81172-81186. PubMed ID: 27783987 [TBL] [Abstract][Full Text] [Related]
27. Bufalin inhibits pancreatic cancer by inducing cell cycle arrest via the c-Myc/NF-κB pathway. Liu X; Xiao XY; Shou QY; Yan JF; Chen L; Fu HY; Wang JC J Ethnopharmacol; 2016 Dec; 193():538-545. PubMed ID: 27686271 [TBL] [Abstract][Full Text] [Related]
28. The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways. Barollo S; Bertazza L; Baldini E; Ulisse S; Cavedon E; Boscaro M; Pezzani R; Mian C Invest New Drugs; 2014 Aug; 32(4):626-35. PubMed ID: 24821574 [TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase. Chung EJ; Brown AP; Asano H; Mandler M; Burgan WE; Carter D; Camphausen K; Citrin D Clin Cancer Res; 2009 May; 15(9):3050-7. PubMed ID: 19366835 [TBL] [Abstract][Full Text] [Related]
30. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cusack JC; Liu R; Houston M; Abendroth K; Elliott PJ; Adams J; Baldwin AS Cancer Res; 2001 May; 61(9):3535-40. PubMed ID: 11325813 [TBL] [Abstract][Full Text] [Related]
31. The preventive effects of hyperoside on lung cancer in vitro by inducing apoptosis and inhibiting proliferation through Caspase-3 and P53 signaling pathway. Liu YH; Liu GH; Mei JJ; Wang J Biomed Pharmacother; 2016 Oct; 83():381-391. PubMed ID: 27419887 [TBL] [Abstract][Full Text] [Related]
32. Shikonin inhibits thyroid cancer cell growth and invasiveness through targeting major signaling pathways. Yang Q; Ji M; Guan H; Shi B; Hou P J Clin Endocrinol Metab; 2013 Dec; 98(12):E1909-17. PubMed ID: 24106286 [TBL] [Abstract][Full Text] [Related]
33. Platycodin D inhibits migration, invasion, and growth of MDA-MB-231 human breast cancer cells via suppression of EGFR-mediated Akt and MAPK pathways. Chun J; Kim YS Chem Biol Interact; 2013 Oct; 205(3):212-21. PubMed ID: 23867902 [TBL] [Abstract][Full Text] [Related]
34. Hydrogen sulfide-releasing naproxen suppresses colon cancer cell growth and inhibits NF-κB signaling. Kodela R; Nath N; Chattopadhyay M; Nesbitt DE; Velázquez-Martínez CA; Kashfi K Drug Des Devel Ther; 2015; 9():4873-82. PubMed ID: 26346117 [TBL] [Abstract][Full Text] [Related]
35. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization. Kuger S; Flentje M; Djuzenova CS Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922 [TBL] [Abstract][Full Text] [Related]
36. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status. Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531 [TBL] [Abstract][Full Text] [Related]
37. Acacetin (5,7-dihydroxy-4'-methoxyflavone) exhibits in vitro and in vivo anticancer activity through the suppression of NF-κB/Akt signaling in prostate cancer cells. Kim HR; Park CG; Jung JY Int J Mol Med; 2014 Feb; 33(2):317-24. PubMed ID: 24285354 [TBL] [Abstract][Full Text] [Related]
38. SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma. Iwahori K; Serada S; Fujimoto M; Ripley B; Nomura S; Mizuguchi H; Shimada K; Takahashi T; Kawase I; Kishimoto T; Naka T Int J Cancer; 2013 Jan; 132(2):459-71. PubMed ID: 22532243 [TBL] [Abstract][Full Text] [Related]
39. Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer. Lin SF; Lin JD; Yeh CN; Huang YT; Chou TC; Wong RJ Endocr Relat Cancer; 2019 Aug; 26(8):727-738. PubMed ID: 31189135 [TBL] [Abstract][Full Text] [Related]
40. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Siwak DR; Shishodia S; Aggarwal BB; Kurzrock R Cancer; 2005 Aug; 104(4):879-90. PubMed ID: 16007726 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]